MedTrace Logo

Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon

NCT00251238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-05-22

Study results available
· View outcomes & findings →

Summary

The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.

Conditions

  • Raynaud Disease

Interventions

DRUG

Ginkgo biloba extract EGb 761

daily Ginkgo biloba extract EGb 761

Sponsors & Collaborators

  • VSM Geneesmiddelen b.v.

    lead INDUSTRY

Principal Investigators

  • Study Department · VSM Geneesmiddelen b.v.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2006-03-31
Completion
2006-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00251238 on ClinicalTrials.gov